Funds and ETFs Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.58 USD -1.25% Intraday chart for Perspective Therapeutics, Inc. +5.33% +293.03%
Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.58 USD
Average target price
1.6 USD
Spread / Average Target
+1.27%
Consensus
  1. Stock Market
  2. Equities
  3. CATX Stock
  4. Funds and ETFs Perspective Therapeutics, Inc.